Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 410 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low dose radiotherapy Clear all
Completed Phase 1Phase 2 Interventional

Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia

NCT00119340
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 2, 2026, 2:14 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 2, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02117024
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Rogers, Arkansas • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 2, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

NCT00490490
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI)
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Phase 1 Interventional

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

NCT01264432
View directory record Official record
Conditions
Adult Solid Neoplasm, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy, Veliparib
Other · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 2, 2026, 2:14 PM EDT
Active, not recruiting Phase 2 Interventional

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

NCT02494700
View directory record Official record
Conditions
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma, Ocular Adnexal Lymphoma, Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma, Orbit Lymphoma
Interventions
External Beam Radiation Therapy, Orbital Radiation
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Not listed Phase 2 Interventional Results available

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01894477
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Interventions
Allogeneic Bone Marrow Transplantation, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation, Treosulfan, Laboratory Biomarker Analysis
Procedure · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

NCT02582775
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
Drug · Radiation · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002703
View directory record Official record
Conditions
Prostate Cancer
Interventions
high-LET heavy ion therapy, low-LET photon therapy
Radiation
Lead sponsor
Proton Radiation Oncology Group
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Loma Linda, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas

NCT05393258
View directory record Official record
Conditions
Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant
Interventions
temporally-modulated pulsed radiotherapy (TMPRT)
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer

NCT05027009
View directory record Official record
Conditions
Melanoma
Interventions
Physical Examination, Solar Simulated Light
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Phase 1 Interventional

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

NCT01303705
View directory record Official record
Conditions
Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer
Interventions
Anti-OX40, Radiation, Cyclophosphamide
Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 2, 2026, 2:14 PM EDT
Recruiting Not applicable Interventional

Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer

NCT07631572
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Cesium-131 Low Dose Radiation (LDR)
Device
Lead sponsor
Denise Fabian
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

NCT03367546
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
Interventions
Blood and Marrow Transplant
Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

NCT05010031
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Active, not recruiting Not applicable Interventional

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

NCT04624256
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Completed No phase listed Observational

Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis

NCT02735746
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Mediastinum Lesion, Radiation Pneumonitis
Interventions
4D Computed Tomography (CT), Cone Beam CT, Low-dose Cinefluorography, Pulmonary Function Tests
Radiation · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 2, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT05357794
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Brentuximab vedotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

NCT02609737
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 2, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

NCT01886105
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy
Drug · Other · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
10 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 2, 2026, 2:14 PM EDT
Withdrawn No phase listed Observational

A CCTA Guided Management Strategy Versus a Standard of Care Strategy in Type 2 NSTEMI

NCT06382402
View directory record Official record
Conditions
Myocardial Injury
Interventions
CCTA scan
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 2, 2026, 2:14 PM EDT
Recruiting Phase 4 Interventional

Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis

NCT07217405
View directory record Official record
Conditions
Osteoarthritis Hand, Osteoarthritis Wrist
Interventions
Corticosteroid injection (CSI), Low-dose radiotherapy (LDRT)
Drug · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 2, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

NCT03398161
View directory record Official record
Conditions
Localized Skin Lesion, Mycosis Fungoides
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 2, 2026, 2:14 PM EDT